Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Phys Rev Lett ; 124(1): 010404, 2020 Jan 10.
Article in English | MEDLINE | ID: mdl-31976727

ABSTRACT

One-dimensional polar gases in deep optical lattices present a severely constrained dynamics due to the interplay between dipolar interactions, energy conservation, and finite bandwidth. The appearance of dynamically bound nearest-neighbor dimers enhances the role of the 1/r^{3} dipolar tail, resulting in the absence of external disorder, in quasi-localization via dimer clustering for very low densities and moderate dipole strengths. Furthermore, even weak dipoles allow for the formation of self-bound superfluid lattice droplets with a finite doping of mobile, but confined, holons. Our results, which can be extrapolated to other power-law interactions, are directly relevant for current and future lattice experiments with magnetic atoms and polar molecules.

2.
Vet Comp Oncol ; 16(4): 511-517, 2018 Dec.
Article in English | MEDLINE | ID: mdl-29961972

ABSTRACT

Mast cell tumours (MCTs) are often diagnosed by cytology based on the identification of purple intracytoplasmic granules with methanolic Romanowsky stains, including May-Grünwald-Giemsa (MGG). In clinical practice, aqueous rapid stains (RS) are commonly used, but mast cell granules may not stain properly. Aim of this prospective study was to investigate the frequency of MCT hypogranularity with RS and its potential implications in tumour identification, cytological grading assessment and recognition of nodal metastatic disease. Cytological preparations of canine primary MCTs and metastatic lymph nodes with subsequent histopathological confirmation were included. For each case, good-quality smears were stained with both MGG and RS and comparatively assessed. Eleven of 60 (18.3%) primary MCTs were hypogranular with RS; 9 of them were histologically high-grade tumours and in 3 cases (5%) a definitive MCT diagnosis could not be made. Accuracy in cytological grading assessment (85%) did not differ between RS and MGG. Thirteen of 28 (46.4%) metastatic lymph nodes were hypogranular with RS and 3 independent observers failed to identify nodal MCT metastases in 7% to 18% of RS-stained smears. This study confirms that, in limited cases, RS can be ineffective in staining MCT granules, particularly in high-grade tumours, thus making diagnosis more dependent on experience and quality of preparations. In dubious cases, methanolic stains should be applied. The use of RS is discouraged for the search of nodal metastases, as the identification of isolated mast cells can be more challenging.


Subject(s)
Coloring Agents/therapeutic use , Dog Diseases/diagnosis , Eosine Yellowish-(YS)/therapeutic use , Mastocytosis/veterinary , Methylene Blue/therapeutic use , Animals , Biopsy, Fine-Needle/veterinary , Dog Diseases/pathology , Dogs , Mast Cells/pathology , Mastocytosis/diagnosis , Mastocytosis/pathology , Mastocytosis, Cutaneous/diagnosis , Mastocytosis, Cutaneous/pathology , Mastocytosis, Cutaneous/veterinary , Mastocytosis, Systemic/diagnosis , Mastocytosis, Systemic/pathology , Mastocytosis, Systemic/veterinary , Prognosis , Prospective Studies
3.
Maturitas ; 54(3): 222-8, 2006 Jun 20.
Article in English | MEDLINE | ID: mdl-16343828

ABSTRACT

OBJECTIVES: Sex steroid hormones are implicated in the cognitive processes of the adult brain. Among studies reporting a positive effect of estrogen replacement therapy (ERT) on cognition, the most consistent evidence is that it enhances verbal memory and visuospatial functions. In the present study we investigated the effect of ERT on cognition and on brain morphology in healthy postmenopausal women, taking into account the distinction in current and past ERT users. METHODS: Participants were postmenopausal nondemented women recruited from the community: ERT users were 40 (23 current users, 17 past users), while never users were 43. Forty of recruited subjects gave consent to undergo 3D high resolution MRI (16 current users, 7 past users and 17 never users). Participants underwent MMSE and a battery of neuropsychological tests measuring memory, language, intelligence, attention and visuo-spatial abilities. RESULTS: The past users group outperformed the never users in four tests: Token test, WCST categories, attentional matrices and Rey's delayed list; the current users group outperformed the never users in the Rey's list test. ERT users had greater grey matter volumes mainly in the cerebellum, but an increase was observed also in the parietal and occipital cortex. CONCLUSIONS: ERT use appears to improve linguistic, attentive and planning abilities. Interestingly, the beneficial effects on cognition were detected mainly in the past users subgroup. Here we propose that the trophic effect of estrogens on cerebellum might account for the observed improvement in cognition.


Subject(s)
Cognition , Estrogen Replacement Therapy , Case-Control Studies , Cerebellum/drug effects , Female , Humans , Middle Aged , Neuropsychological Tests , Postmenopause
4.
Curr Alzheimer Res ; 1(3): 215-8, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15975068

ABSTRACT

Genetic factors are involved in the aetiology of dementias. Three genes have been identified which, when mutated, cause Familial Alzheimer disease (FAD): the presenilin-1 (PS1), the presenilin-2 (PS2) and the amyloid precursor protein (APP) genes. Together, these mutations are responsible for 30-50% of the cases with autosomal dominant Alzheimer disease (AD), and for about 5% of all AD cases. While over 130 mutations have been identified in PS1, mutations in PS2 and APP are rarer, since only 10 and 22 mutations, respectively, have been found in these FAD genes. Instead, mutations in the MAPT gene were associated with Familial Frontotemporal dementia (FFTD) linked to chromosome 17 (FTDP-17). Frontotemporal dementia (FTD) can occur in a sporadic form, but in 30-50% of cases there is a positive family history of dementia. In this study, we determined the spectrum of mutations and the relative contribution of the above mentioned four genes in our Italian clinical series of patients with a positive family history of dementia.


Subject(s)
Amyloid beta-Protein Precursor/genetics , Dementia/genetics , Gene Frequency , Membrane Proteins/genetics , Mutation , Nerve Tissue Proteins/genetics , Aged , Alzheimer Disease/genetics , Base Sequence , Chromosome Mapping , Chromosomes, Human, Pair 17 , Female , Humans , Italy , Male , Middle Aged , Presenilin-1 , Presenilin-2 , tau Proteins
5.
J Neural Transm (Vienna) ; 110(9): 1029-39, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12938025

ABSTRACT

Defects in energy metabolism and oxidative stress play an important role in the pathogenesis of Alzheimer's Disease (AD). In sporadic AD cases, presenilin 2 (PS2) mRNA levels are decreased in brain areas affected by the disease. The aim of the present study was to investigate whether mitochondrial dysfunction might influence PS2 gene expression. We demonstrated that the inhibition of energy metabolism by sodium azide down-regulates PS2 gene expression through modification of promoter activity. No one of the analyzed transcription factors, sensitive to redox status of the cell, could explain this effect. Azide effect on PS2 expression was completely inhibited by the addition of an antioxidant suggesting that the imbalance of the cellular redox homeostasis modulates the expression of this gene.


Subject(s)
Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Brain/metabolism , Energy Metabolism/genetics , Membrane Proteins/genetics , Mitochondria/metabolism , Antioxidants/pharmacology , Brain/physiopathology , Cell Line, Tumor , Down-Regulation/drug effects , Down-Regulation/genetics , Energy Metabolism/drug effects , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , Humans , Oxidation-Reduction/drug effects , Oxidative Stress/drug effects , Oxidative Stress/genetics , Presenilin-2 , Promoter Regions, Genetic/genetics , RNA, Messenger/metabolism , Sodium Azide/pharmacology , Transcription Factors/drug effects , Transcription Factors/physiology
6.
Exp Neurol ; 182(2): 335-45, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12895444

ABSTRACT

Brain deposition of the amyloid-beta protein (Abeta) is a frequent complication of Down's syndrome (DS) patients. Abeta peptide is generated by endoproteolytic processing of Abeta precursor protein by gamma and beta secretases. Recently a transmembrane aspartyl protease, BACE, has been identified as the beta-secretase, and its homologous BACE-2 has also been described. BACE-2 gene resides on chromosome 21 in the obligate DS region. It cleaves Abeta precursor protein at its beta site and more efficiently at a different site within Abeta. In the present study we characterized the BACE-2 gene and protein expression in the DS patients and healthy control. We analyzed, by using a nonradioactive ribonuclease protection assay, the levels of BACE-2 mRNA expression in primary skin fibroblasts. The analysis revealed a 2.6-fold increase in BACE-2 mRNA levels in the DS group compared to the levels observed in the control group. Western blot analysis revealed no difference between DS and control in BACE-2 protein levels in the intracellular compartment. In the medium conditioned by fibroblast, we revealed an evident secretion of BACE-2 protein, represented by two different molecular weights, remarkably increased in DS fibroblasts. BACE-2 overexpression was also confirmed in the DS fetal brains and human neural embryonic DS stem cells in which conditioned media BACE-2 was secreted. These data highlight the importance of the extracellular compartment where BACE-2 overexpression could play a role in plaque formation in DS patients.


Subject(s)
Aspartic Acid Endopeptidases/biosynthesis , Brain/enzymology , Down Syndrome/enzymology , Fibroblasts/enzymology , Stem Cells/enzymology , Adult , Amyloid Precursor Protein Secretases , Aspartic Acid Endopeptidases/genetics , Aspartic Acid Endopeptidases/metabolism , Blotting, Western , Brain/embryology , Brain Chemistry , Cells, Cultured , Culture Media, Conditioned/chemistry , Fibroblasts/cytology , Fibroblasts/metabolism , Humans , Molecular Weight , Neurons/cytology , Neurons/enzymology , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Reference Values , Stem Cells/cytology , Stem Cells/metabolism
7.
Exp Cell Res ; 269(2): 256-65, 2001 Oct 01.
Article in English | MEDLINE | ID: mdl-11570818

ABSTRACT

Mutations in gene encoding presenilin 1 (PS1) are responsible for the majority of familial Alzheimer's disease (FAD) cases. We studied PS1 localization in HEK293 cells and in primary neurons obtained from rat cortex and hippocampus. We first demonstrated that PS1-CTF, but neither PS1-FL nor PS1-NTF, is released into the medium as a soluble and membrane-associated form. After induction of apoptosis with staurosporine (Sts), we observed a dramatic increase in the level of PS1-CTF in the medium, both in HEK293 and in primary neurons. Immunocytochemical analysis suggested that the release of PS1-CTF might occur via membrane shedding. Abeta(1-42) treatment reduced PS1-CTF extracellular levels. This decrease was strongly associated to an impaired secretion of sAPP fragments, thus suggesting a role of PS1-CTF in the control of trafficking and generation of APP fragments.


Subject(s)
Membrane Proteins/chemistry , Alzheimer Disease/metabolism , Amyloid beta-Peptides/pharmacology , Animals , Apoptosis , Blotting, Western , Cell Line , Cells, Cultured , Cerebral Cortex/metabolism , Enzyme Inhibitors/pharmacology , Extracellular Matrix/metabolism , Hippocampus/metabolism , Humans , Immunohistochemistry , In Situ Nick-End Labeling , Microscopy, Fluorescence , Neurons/metabolism , Peptide Fragments/pharmacology , Peptides/pharmacology , Presenilin-1 , Protein Binding , Protein Structure, Tertiary , Rats , Rats, Wistar , Staurosporine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL